Recently, awareness of HER2-low breast cancer has surged significantly, following the DESTINY-Breast 04 study, which demonstrated the effectiveness of HER2-targeted therapy in patients with HER2-low metastatic breast cancer [23]. This evidence concerns the gene ERBB2 and breast carcinoma.